Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy

Cancer Cell

Volumn 27, Issue 6, 2015, Pages 837-851

  Stratikopoulos, Elias E ^a   Dendy, Meaghan ^a   Szabolcs, Matthias ^b   Khaykin, Alan J ^a   Lefebvre, Celine ^c   Zhou, Ming Ming ^a   Parsons, Ramon ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN KINASE B; TYROSINE KINASE RECEPTOR; BRD4 PROTEIN, HUMAN; BRD4 PROTEIN, MOUSE; NUCLEAR PROTEIN; PIK3CA PROTEIN, HUMAN; PIK3CA PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; BREAST METASTASIS; CANCER CELL; CANCER REGRESSION; CANCER RESISTANCE; CELL DENSITY; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; FEEDBACK SYSTEM; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL LINE; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; GENETICS; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; PROTEIN DOMAIN; RANDOMIZATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN KINASE INHIBITORS; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930582576     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.05.006     Document Type: Article

References (58)

1. Andrechek E.R., Cardiff R.D., Chang J.T., Gatza M.L., Acharya C.R., Potti A., Nevins J.R. Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc. Natl. Acad. Sci. USA 2009, 106:16387-16392.
2. Asangani I.A., Dommeti V.L., Wang X., Malik R., Cieslik M., Yang R., Escara-Wilke J., Wilder-Romans K., Dhanireddy S., Engelke C., et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 2014, 510:278-282.
3. Bader A.G., Kang S., Zhao L., Vogt P.K. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 2005, 5:921-929.
4. Bandopadhayay P., Bergthold G., Nguyen B., Schubert S., Gholamin S., Tang Y., Bolin S., Schumacher S.E., Zeid R., Masoud S., et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin. Cancer Res. 2014, 20:912-925.
5. Bendell J.C., Rodon J., Burris H.A., de Jonge M., Verweij J., Birle D., Demanse D., De Buck S.S., Ru Q.C., Peters M., et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J.Clin. Oncol. 2012, 30:282-290.
6. Britschgi A., Andraos R., Brinkhaus H., Klebba I., Romanet V., Müller U., Murakami M., Radimerski T., Bentires-Alj M. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 2012, 22:796-811.
7. Cardiff R.D., Sinn E., Muller W., Leder P. Transgenic oncogene mice. Tumor phenotype predicts genotype. Am. J. Pathol. 1991, 139:495-501.
8. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., Majumder P.K., Baselga J., Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71.
9. Cho H., Herzka T., Zheng W., Qi J., Wilkinson J.E., Bradner J.E., Robinson B.D., Castillo-Martin M., Cordon-Cardo C., Trotman L.C. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov. 2014, 4:318-333.
10. Costa C., Ebi H., Martini M., Beausoleil S.A., Faber A.C., Jakubik C.T., Huang A., Wang Y., Nishtala M., Hall B., et al. Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Cancer Cell 2015, 27:97-108.
11. Dawson M.A., Prinjha R.K., Dittmann A., Giotopoulos G., Bantscheff M., Chan W.I., Robson S.C., Chung C.W., Hopf C., Savitski M.M., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478:529-533.
12. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
13. Duncan J.S., Whittle M.C., Nakamura K., Abell A.N., Midland A.A., Zawistowski J.S., Johnson N.L., Granger D.A., Jordan N.V., Darr D.B., et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149:307-321.
14. Elkabets M., Vora S., Juric D., Morse N., Mino-Kenudson M., Muranen T., Tao J., Campos A.B., Rodon J., Ibrahim Y.H., et al. mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in PIK3CA-mutant breast cancer. Sci. Transl. Med. 2013, 5:196ra199.
15. Feng Q., Zhang Z., Shea M.J., Creighton C.J., Coarfa C., Hilsenbeck S.G., Lanz R., He B., Wang L., Fu X., et al. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014, 24:809-819.
16. Fernandez S.V., Robertson F.M., Pei J., Aburto-Chumpitaz L., Mu Z., Chu K., Alpaugh R.K., Huang Y., Cao Y., Ye Z., et al. Inflammatory breast cancer (IBC): clues for targeted therapies. Breast Cancer Res. Treat. 2013, 140:23-33.
17. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
18. Folkes A.J., Ahmadi K., Alderton W.K., Alix S., Baker S.J., Box G., Chuckowree I.S., Clarke P.A., Depledge P., Eccles S.A., et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J.Med. Chem. 2008, 51:5522-5532.
19. Gera J.F., Mellinghoff I.K., Shi Y., Rettig M.B., Tran C., Hsu J.H., Sawyers C.L., Lichtenstein A.K. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J.Biol. Chem. 2004, 279:2737-2746.
20. Gregory M.A., Qi Y., Hann S.R. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J.Biol. Chem. 2003, 278:51606-51612.
21. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004, 18:1926-1945.
22. Ilic N., Utermark T., Widlund H.R., Roberts T.M. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc. Natl. Acad. Sci. USA 2011, 108:E699-E708.
23. Janku F., Wheler J.J., Westin S.N., Moulder S.L., Naing A., Tsimberidou A.M., Fu S., Falchook G.S., Hong D.S., Garrido-Laguna I., et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J.Clin. Oncol. 2012, 30:777-782.
24. Jia S., Liu Z., Zhang S., Liu P., Zhang L., Lee S.H., Zhang J., Signoretti S., Loda M., Roberts T.M., Zhao J.J. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008, 454:776-779.
25. Kanno T., Kanno Y., LeRoy G., Campos E., Sun H.W., Brooks S.R., Vahedi G., Heightman T.D., Garcia B.A., Reinberg D., et al. BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. Nat. Struct. Mol. Biol. 2014, 21:1047-1057.
26. Li G., Robinson G.W., Lesche R., Martinez-Diaz H., Jiang Z., Rozengurt N., Wagner K.U., Wu D.C., Lane T.F., Liu X., et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 2002, 129:4159-4170.
27. Liu P., Cheng H., Santiago S., Raeder M., Zhang F., Isabella A., Yang J., Semaan D.J., Chen C., Fox E.A., et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat. Med. 2011, 17:1116-1120.
28. Liu W., Ma Q., Wong K., Li W., Ohgi K., Zhang J., Aggarwal A.K., Rosenfeld M.G. Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release. Cell 2013, 155:1581-1595.
29. Lockwood W.W., Zejnullahu K., Bradner J.E., Varmus H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition ofBET epigenetic signaling proteins. Proc. Natl. Acad. Sci. USA 2012, 109:19408-19413.
30. Lovén J., Hoke H.A., Lin C.Y., Lau A., Orlando D.A., Vakoc C.R., Bradner J.E., Lee T.I., Young R.A. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
31. Ludwig T., Fisher P., Murty V., Efstratiadis A. Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice. Oncogene 2001, 20:3937-3948.
32. Lynch M., Fitzgerald C., Johnston K.A., Wang S., Schmidt E.V. Activated eIF4E-binding protein slows G1 progression and blocks transformation by c-myc without inhibiting cell growth. J.Biol. Chem. 2004, 279:3327-3339.
33. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
34. Martini M., Ciraolo E., Gulluni F., Hirsch E. Targeting PI3K in cancer: any good news?. Front Oncol 2013, 3:108.
35. Montero-Conde C., Ruiz-Llorente S., Dominguez J.M., Knauf J.A., Viale A., Sherman E.J., Ryder M., Ghossein R.A., Rosen N., Fagin J.A. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013, 3:520-533.
36. Muellner M.K., Uras I.Z., Gapp B.V., Kerzendorfer C., Smida M., Lechtermann H., Craig-Mueller N., Colinge J., Duernberger G., Nijman S.M. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat. Chem. Biol. 2011, 7:787-793.
37. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
38. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
39. Rahl P.B., Lin C.Y., Seila A.C., Flynn R.A., McCuine S., Burge C.B., Sharp P.A., Young R.A. c-Myc regulates transcriptional pause release. Cell 2010, 141:432-445.
40. Rodrik-Outmezguine V.S., Chandarlapaty S., Pagano N.C., Poulikakos P.I., Scaltriti M., Moskatel E., Baselga J., Guichard S., Rosen N. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011, 1:248-259.
41. Schwartz S., Wongvipat J., Trigwell C.B., Hancox U., Carver B.S., Rodrik-Outmezguine V., Will M., Yellen P., de Stanchina E., Baselga J., et al. Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell 2015, 27:109-122.
42. Segura M.F., Fontanals-Cirera B., Gaziel-Sovran A., Guijarro M.V., Hanniford D., Zhang G., González-Gomez P., Morante M., Jubierre L., Zhang W., et al. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res. 2013, 73:6264-6276.
43. Serra V., Scaltriti M., Prudkin L., Eichhorn P.J., Ibrahim Y.H., Chandarlapaty S., Markman B., Rodriguez O., Guzman M., Rodriguez S., et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011, 30:2547-2557.
44. Serra V., Eichhorn P.J., García-García C., Ibrahim Y.H., Prudkin L., Sánchez G., Rodríguez O., Antón P., Parra J.L., Marlow S., et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J.Clin. Invest. 2013, 123:2551-2563.
45. She Q.B., Chandarlapaty S., Ye Q., Lobo J., Haskell K.M., Leander K.R., DeFeo-Jones D., Huber H.E., Rosen N. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 2008, 3:e3065.
46. Shi J., Wang Y., Zeng L., Wu Y., Deng J., Zhang Q., Lin Y., Li J., Kang T., Tao M., et al. Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell 2014, 25:210-225.
47. Soucek L., Evan G.I. The ups and downs of Myc biology. Curr. Opin. Genet. Dev. 2010, 20:91-95.
48. Stewart T.A., Pattengale P.K., Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 1984, 38:627-637.
49. Stuhlmiller T.J., Miller S.M., Zawistowski J.S., Nakamura K., Beltran A.S., Duncan J.S., Angus S.P., Collins K.A., Granger D.A., Reuther R.A., et al. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Rep. 2015, 11:390-404.
50. Tenbaum S.P., Ordóñez-Morán P., Puig I., Chicote I., Arqués O., Landolfi S., Fernández Y., Herance J.R., Gispert J.D., Mendizabal L., et al. β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat. Med. 2012, 18:892-901.
51. Torbett N.E., Luna-Moran A., Knight Z.A., Houk A., Moasser M., Weiss W., Shokat K.M., Stokoe D. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem. J. 2008, 415:97-110.
52. Wee S., Wiederschain D., Maira S.M., Loo A., Miller C., deBeaumont R., Stegmeier F., Yao Y.M., Lengauer C. PTEN-deficient cancers depend on PIK3CB. Proc. Natl. Acad. Sci. USA 2008, 105:13057-13062.
53. Whyte W.A., Orlando D.A., Hnisz D., Abraham B.J., Lin C.Y., Kagey M.H., Rahl P.B., Lee T.I., Young R.A. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 2013, 153:307-319.
54. Yeh E., Cunningham M., Arnold H., Chasse D., Monteith T., Ivaldi G., Hahn W.C., Stukenberg P.T., Shenolikar S., Uchida T., et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat. Cell Biol. 2004, 6:308-318.
55. Zhang G., Liu R., Zhong Y., Plotnikov A.N., Zhang W., Zeng L., Rusinova E., Gerona-Nevarro G., Moshkina N., Joshua J., et al. Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J.Biol. Chem. 2012, 287:28840-28851.
56. Zhao J.J., Gjoerup O.V., Subramanian R.R., Cheng Y., Chen W., Roberts T.M., Hahn W.C. Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell 2003, 3:483-495.
57. Zhu J., Blenis J., Yuan J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc. Natl. Acad. Sci. USA 2008, 105:6584-6589.
58. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.